Regeneron Pharmaceuticals Inc

REGN 
(NASDAQ) 
 
$ 333.34 <%= Resources.Global.txtDown %>
Updated 17/04/2019
Change % -2.81% Stock price decreasing
Change -9.63 Stock price decreasing
Volume 1,367,374
High $ 347.49
Low $ 332.23
Open $ 346.40
ISIN
Prev close $ 342.97
# of shares 107.37M
Market cap 35,789M USD
Intraday

Market closed
Regeneron Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  333.34 -13.0% Stock price decreasing -17.2% Stock price decreasing -20.4% Stock price decreasing -14.5% Stock price decreasing 6.1% Stock price increasing
Powered by TradingView

News about Regeneron Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 09:58:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB1 - 2019-04-21 10:58:06 - 2019-04-21 09:58:06 - 1000 - Website: OKAY